孕妇耐多药/利福平耐药结核与全口服6个月方案:南非患者系列经验
南非前瞻性观察研究纳入2023年9月至2025年1月KwaZulu-Natal地区25例耐多药/利福平耐药结核孕妇,其中21例接受含贝达喹啉、德拉马尼、利奈唑胺及左氧氟沙星或氯法齐明的全口服6个月方案。21例中18例(86%)治疗转归良好,但10例(48%)发生贫血;所有21例婴儿活产,18例12月龄评估婴儿中10例(56%)存在可能或确认的不良转归。
要点
- BDLLfx/BDLCfz方案在孕妇中治疗转归良好(18/21,86%),但贫血常见(10/21,48%)。
- 所有21例婴儿活产,中位胎龄39周,中位出生体重3160g。
- 12月龄评估的18例婴儿中10例(56%)存在可能或确认的不良转归。
核心结论
- 有限数据提示BDLLfx/BDLCfz方案在孕妇中较既往方案改善治疗和妊娠结局。
- 婴儿不良结局发生率较高,需关注。
研究设计与样本
- 前瞻性观察性研究,纳入2023年9月至2025年1月南非KwaZulu-Natal地区25例耐多药/利福平耐药结核孕妇。
- 21例接受BDLLfx/BDLCfz方案,通过持续病历审查收集结局,婴儿在6周、6个月和12个月进行临床评估。
主要发现
- 21例治疗孕妇中12例(57%)诊断HIV感染。
- 21例中18例(86%)治疗转归良好,10例(48%)发生贫血。
- 所有21例婴儿活产,中位胎龄39周(IQR 38-40周),中位出生体重3160g(IQR 2818-3308g)。
- 3例孕妇妊娠结局不良,婴儿早产(2例低出生体重,1例呼吸窘迫综合征)。
- 12月龄评估的18例婴儿中10例(56%)存在可能或确认的不良结局;2例确认先天畸形,3例可能先天畸形,仅1例有孕早期药物暴露;1例死亡,1例诊断MDR/RR-TB并开始治疗,3例有结核症状/体征需转诊。
关键数值与推荐
- BDLLfx/BDLCfz方案指含贝达喹啉、德拉马尼、利奈唑胺及左氧氟沙星或氯法齐明的全口服6个月方案。
临床怎么用
- 孕妇MDR/RR-TB可考虑BDLLfx/BDLCfz方案,但需监测贫血。
- 婴儿需在6周、6个月和12个月进行临床评估,关注先天畸形和结核症状。
局限性
- 样本量小(25例孕妇,21例治疗),为观察性研究,数据有限。
- 婴儿不良结局原因未明确,仅1例有孕早期药物暴露。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is limited experience of the all-oral 6-month regimens containing bedaquiline, delamanid, linezolid, and levofloxacin or clofazimine (BDLLfx/BDLCfz) in pregnant women with multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB). We report maternal treatment, pregnancy, and infant outcomes to 12 months of age in a cohort of pregnant women treated with these regimens. METHODS: We included pregnant women treated for MDR/RR-TB from September 2023 to January 2025 in KwaZulu-Natal, South Africa, in a prospective observational study. Outcomes were collected through ongoing record reviews. Infant clinical assessments were conducted at 6 weeks, 6 months, and 12 months. RESULTS: Of 25 pregnant women with MDR/RR-TB, 21 received BDLLfx/BDLCfz; 12 (57%) were diagnosed with human immunodeficiency virus. Although 10 of the 21 (48%) treated women developed anemia, 18 (86%) had favorable treatment outcomes. All 21 infants were born alive, with a median gestational age 39 weeks (interquartile range [IQR], 38-40 weeks) and median birth weight 3160 g (IQR, 2818-3308 g). Three women had unfavorable pregnancy outcomes, with infants born prematurely (2 with low birth weight and 1 who developed respiratory distress syndrome). Of the 18 infants evaluated at 12 months, 10 (56%) had possible or confirmed unfavorable outcomes. Two infants had confirmed congenital anomalies and 3 possible congenital anomalies, but only 1 had first-trimester drug exposure. One infant died, another was diagnosed with MDR/RR-TB and started on treatment, and 3 infants had signs/symptoms of tuberculosis, necessitating referral for care. CONCLUSIONS: These limited data suggest that in pregnant women, the BDLLfx/BDLCfz regimens have improved treatment and pregnancy outcomes compared to prior regimens. However, there is a high prevalence of unfavorable infant outcomes.
引用
- Loveday M, Clarence E, Hlangu S, et al. Pregnant Women With Multidrug-Resistant/Rifampicin-Resistant Tuberculosis and the All-Oral 6-Month Regimen: Experiences From a Patient Series in South Africa. Clin Infect Dis. 2026. PMID: 41564894. doi:10.1093/cid/ciag032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。